Headquartered in Hayward, California, Aradigm Corp. engages in developing inhalation drug products that enhance the quality of life of patients with severe pulmonary disease. Founded in 1991, the company has a team of scientists, engineers, and clinical experts who have been at the forefront of development of advanced inhalation delivery products.

Aradigm Corp.’s team pioneered the AERx® iDMS pulmonary delivery of insulin used in Phase 3 clinical trials conducted by their partner Novo Nordisk. Today, with experience and expertise in inhalation delivery, Aradigm is positioning their company to develop a portfolio of their own products to treat patients with severe respiratory diseases. The company’s current pipeline includes products undergoing development by Aradigm, or in partnerships with others, for the treatment of cystic fibrosis, inhalation anthrax, and pulmonary arterial hypertension. Aradigm Corp. is also investigating the use of their technology for tobacco smoking cessation therapy.

Aradigm’s AERx pulmonary drug delivery platform demonstrated performance that is highly efficient and precise as an inhalation system. The performance of the AERx platform is due to its unique fine mist aerosol generation systems combined with patented breath control technology. For each therapeutic application, the AERx platform is customizable to deliver drugs and biologics to treat lung diseases topically or to transport therapeutics through the lung and into the bloodstream.

Aradigm Corp.’s corporate strategy is to continue development of proprietary respiratory disease therapies, and pursue regulatory pathways that reduce the time, costs, and risks associated with product development. In addition, their strategy is to conserve capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing. They are also working to deploy a specialized sales and marketing force to meet the unique needs of pulmonologists and sub-specialists in the United States. On top of all that, they are looking at out-licensing technology and intellectual property assets for applications that lie outside their strategic interests and core expertise.